Note: This guideline has been updated. The National Guideline Clearinghouse (NGC) is working to update this summary. The recommendations that follow are based on the previous version of the guideline.
The level of evidence grades (A-D) are provided for the most significant recommendations and are defined at the end of the "Major Recommendations" field.
| Recommendations |
Birth |
1 mo |
2 mos |
4 mos |
6 mos |
12 mos |
15 mos |
18 mos |
24 mos |
| Health, developmental and risk assessments |
X |
X |
X |
X |
X |
X |
X |
X |
X |
Parental education and counseling:
- Immunizations, nutrition, breast-feeding [A], physical activity, dental health, child abuse, depression, alcohol/drug abuse, anxiety, stress reduction, coping skills
- Motor vehicle safety - Rear facing car seat when riding in a motor vehicle until 1 year and 20 pounds [B].
- Poison prevention - Keep National Poison Control numbers readily accessible; use child resistant containers
- Burn prevention - Install smoke detectors and test bi-annually; carbon monoxide detectors; water heater temperature and fire prevention
- Injury prevention - Use of gates; never leave infant unattended on changing table; water safety; CPR training
- SIDS and infant sleep positioning - Place infants on their back [B]
|
X |
X |
X |
X |
X |
X |
X |
X |
X |
| Tobacco Use Screening: Establish tobacco use and second-hand exposure |
X |
X |
X |
X |
X |
X |
X |
X |
X |
| Neonatal Screening: Newborn metabolic screening prior to hospital discharge >24 hours of age [D] |
X
>24 hours of age
|
|
|
|
|
|
|
|
|
| Blood Lead Testing [B] |
|
|
|
|
|
X |
|
|
|
Abbreviations: CPR, cardiopulmonary resuscitation; SIDS, sudden infant death syndrome
Immunizations
- Consult the Advisory Committee on Immunization Practices (ACIP) website (www.cdc.gov/nip/acip/) for most updated immunization schedules for routine and high risk populations.
- Use combination vaccines to minimize the number of injections
- Update the Michigan Care Improvement Registry (MCIR)
| Vaccines |
Birth |
1 mo |
2 mos |
4 mos |
6 mos |
12 mos |
15 mos |
18 mos |
24 mos |
| DTaP [A] |
|
|
X |
X |
X |
X |
|
| IPV |
|
|
X |
X |
X |
|
| MMR (MMRV) [A] |
|
|
|
|
|
X |
|
|
| Varicella [A] |
|
|
|
|
|
X |
|
|
| Pneumococcal (PCV7) |
|
|
X |
X |
X |
X |
|
|
| Hib [A] |
|
|
X |
X |
X |
X |
|
|
| Rotavirus |
|
|
X |
X |
X |
|
|
|
|
Hep B [A]
Schedule 1
|
X |
X |
|
X |
|
Hep B [A]
Schedule 2
|
|
X |
X |
X |
|
| Hep A |
|
|
|
|
|
X |
X |
| Influenza [B] |
|
|
|
|
X (6 to 59 months, annually) |
Abbreviations: DTaP, diphtheria, tetanus, acellular pertussis; Hep A, hepatitis A; Hep B, hepatitis B; Hib, Haemophilus influenzae type b; IPV, inactivated poliovirus vaccine; MMR, measles, mumps, rubella; MMRV, measles, mumps, rubella, varicella; PCV7, pneumococcal 7 valent conjugated polysaccharide vaccine
Definitions:
Levels of Evidence for the Most Significant Recommendations
- Randomized controlled trials
- Controlled trials, no randomization
- Observational studies
- Opinion of expert panel